<DOC>
	<DOCNO>NCT02317796</DOCNO>
	<brief_summary>A Multi-center , Double Blind , Randomized , Placebo-controlled , Parallel Group Phase IIa Study MLR-1023 Adult Subjects With Uncontrolled Type 2 Diabetes</brief_summary>
	<brief_title>Adult Subjects With Uncontrolled Type 2 Diabetes</brief_title>
	<detailed_description>Objectives 1 . To assess safety , tolerability initial anti-diabetic activity MLR-1023 subject uncontrolled mild moderate type 2 diabetes mellitus 2 . To evaluate pharmacokinetics MLR-1023 major metabolite , MLR-1023-M1 follow 28 day repeat dose Design Outcomes The study randomize , double blind , placebo-controlled , parallel group study MLR-1023 adult subject uncontrolled type 2 diabetes mellitus diet exercise therapy . A subset subject per dose group additional sample analyze measure sign MLR-1023 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . Diagnosed uncontrolled T2DM receive diet exercise therapy least 3 month prior screen , age ≥ 18 ≤ 75 year 2 . Females must postmenopausal , unable conceive , test negative pregnancy via blood test use barrier contraception 3 . BMI range ≥ 20 ≤ 40 kg/m2 4 . Fasting plasma glucose value 240 mg/dL screening , washout ( visit 2 ) placebo runin ( visit 3 ) 5 . ( ) naïve ( ii ) currently use discontinue metformin ( iii ) prior exposure antidiabetic agent metformin ≥ 6 month prior screen 1 . History Type 1 diabetes 2 . History 1 episode severe hypoglycemia within 6 month prior screen , current diagnosis hypoglycemia unawareness . 3 . Hospitalizations Emergency room visit would impact patient safety data interpretation : 1 . Due poor glucose control 6 month prior screen 2 . Any bariatric surgical procedure weight loss . 4 . Significant change body weight ( &gt; 10 % ) 3 month screen 5 . Proliferative retinopathy maculopathy within 6 month screen require acute treatment , severe neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>